DC-CIK联合同步放化疗治疗非小细胞肺癌的效果  

The effectiveness of combined application of DC-CIK and synchronous radiotherapy and chemotherapy in treatment of non-small cell lung cancers

作　　者：钟琼[1] 吴仁瑞[1] 曾治民[1] 

机构地区：[1]江西省赣州市人民医院肿瘤科,江西赣州341000

出　　处：《中国当代医药》2016年第20期81-83,共3页China Modern Medicine

摘　　要：目的 探讨生物免疫疗法DC-CIK联合同步放化疗对非小细胞肺癌患者放射性肺炎的控制效果。方法 选取2013年1月-2016年1月我院收治的60例中晚期非小细胞肺癌患者为研究对象,根据治疗方案不同分为观察组32例和对照组28例,对照组患者采用单纯同步放化疗治疗,观察组则采用同步放化疗序贯DC-CIK免疫治疗。统计两组患者的近期疗效及不良反应情况,评估DC-CIK免疫治疗对放射性肺炎的预防效果。结果 观察组临床有效率为87.50%（26/32）,对照组85.72%（23/28）,观察组略高于对照组,但差异无统计学意义（χ^2=2.019,P〉0.05）。观察组患者的白细胞减少、放射性肺炎反应发生率分别为53.13%（17/32）、12.50%（4/32）,与对照组的82.14%（23/28）、53.57%（15/28）相比显著减少,差异有统计学意义（P〈0.05）。结论 DC-CIK免疫疗法能够在一定程度上提高放化疗非小细胞肺癌患者的免疫功能,从而提高近期治疗效果,降低放射性肺炎等不良反应的发生率,具有较高的应用价值。Objective To explore the effectiveness of combined application of DC-CIK and synchronous radiotherapy and chemotherapy in the treatment of non-small cell lung cancer patients with radiation pneumonia.Methods Altogether 60 patients with middle and advanced stage non-small cell lung cancers treated in the hospital from January 2013 to January 2016 were selected and divided into observation group （32 cases） and control group （28 cases） according to different treatment plans.Control group was treated with synchronous radiotherapy and chemotherapy,while observation group was treated with the combination of DC-CIK and radiotherapy and chemotherapy sequential immunotherapy. Statistics of the efficacy and adverse reactions between two groups was made to evaluate the effectiveness of application of DC-CIK immunotherapy in prevention of radioactive pneumonia.Results The clinical effective rate in observation group was 87.50% （26/32）,slightly higher than 85.72% （23/28） in the the control group without significant difference （χ^2=-2.019,P〉0.05）.The leukopenia and pneumonitis reaction rate in the observation group was 53.13% （17/32） and 12.50% （4/32） respectively,and significantly decreased in comparison with 82.14% （23/28） and 53.57% （15/28） in the control group,with statistically significant difference （P〈0.05）.Conclusion DC-CIK immunotherapy can improve chemotherapy non-immune functions in patients with non-small cell lung cancer to some extent,so as to improve the recent therapeutic effect and reduce the incidence of adverse reaction of radiation pneumonia,which is of higher application value.

关 键 词：非小细胞肺癌 放射性肺炎 DC-CIK 

分 类 号：R734.2[医药卫生—肿瘤]